Knockdown of WIPF1 in glioblastoma and breast cancer cells expressing mutant p53 reduced the proliferation and growth ability of cancer stem-like cells and decreased the expression of cancer stem-like markers such as CD44, CD133, and TAZ/YAP. This evidence concerns the gene CD44 and cancer.